Key facts
- NFlection Therapeutics’s last known valuation is $156.0M (Aug 2025).
- It has raised $65.5M across 3 recorded rounds; the latest was Seed Round ($4.0M) in Jul 2023.
- Notable investors include F-Prime Capital, Eight Roads, venBio, Children's Tumor Foundation, U.S. Department of Health and Human Services.
- NFlection Therapeutics has filed 4 Form Ds with the SEC since 2017, most recently Jul 2023 ($4.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for NFlection Therapeutics
Funding rounds
3 roundsAbout NFlection Therapeutics
Developer of topical therapies designed to address rare skin disorders associated with abnormal RAS pathway activity. The company offers MEK inhibitors applied to the skin, enabling patients with uncommon dermatological conditions to receive localized treatment focused on disease control.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2014
- Employees
- 6
- Website
- nflection.com/
- Ownership
- Privately Held (backing)
NFlection Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NFlection Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NFlection Therapeutics in its N-PORT filings yet. We sweep new filings monthly.